BARD1 Life Sciences Stock | BD1.AX | AU000000BD12 | A2AL50

Date	BARD1 Life Sciences Price
2/21/2022	1.03 undefined
2/18/2022	1.06 undefined

Date	BARD1 Life Sciences Revenue	BARD1 Life Sciences EBIT	BARD1 Life Sciences Net Income
2021	510,980 undefined	-6.59 M undefined	-11.15 M undefined
2020	98,390 undefined	-2.33 M undefined	-3.25 M undefined
2019	8,730 undefined	-1.77 M undefined	-1.72 M undefined
2018	7,210 undefined	-1.92 M undefined	-1.82 M undefined
2017	4,200 undefined	-2.59 M undefined	-2.6 M undefined
2016	0 undefined	-130,000 undefined	-2.84 M undefined
2015	0 undefined	0 undefined	0 undefined
2014	0 undefined	0 undefined	0 undefined
2013	10,000 undefined	-610,000 undefined	-10.52 M undefined
2012	300,000 undefined	-590,000 undefined	-10.45 M undefined
2011	200,000 undefined	-1.03 M undefined	-1.56 M undefined
2010	1.46 M undefined	480,000 undefined	-1.61 M undefined
2009	6.93 M undefined	5.78 M undefined	3.76 M undefined
2008	5.88 M undefined	4.85 M undefined	3.16 M undefined
2007	30,000 undefined	700,000 undefined	-11.09 M undefined
2006	190,000 undefined	-3.52 M undefined	-10.22 M undefined
2005	370,000 undefined	-2.27 M undefined	-3.13 M undefined
2004	630,000 undefined	-690,000 undefined	-1.13 M undefined
2003	1.28 M undefined	-580,000 undefined	-1.34 M undefined
2002	2.25 M undefined	-30,000 undefined	-180,000 undefined

	Revenue	EBIT	Net Income
2002	2.25 M AUD	-30,000 AUD	-180,000 AUD
2003	1.28 M AUD	-580,000 AUD	-1.34 M AUD
2004	630,000 AUD	-690,000 AUD	-1.13 M AUD
2005	370,000 AUD	-2.27 M AUD	-3.13 M AUD
2006	190,000 AUD	-3.52 M AUD	-10.22 M AUD
2007	30,000 AUD	700,000 AUD	-11.09 M AUD
2008	5.88 M AUD	4.85 M AUD	3.16 M AUD
2009	6.93 M AUD	5.78 M AUD	3.76 M AUD
2010	1.46 M AUD	480,000 AUD	-1.61 M AUD
2011	200,000 AUD	-1.03 M AUD	-1.56 M AUD
2012	300,000 AUD	-590,000 AUD	-10.45 M AUD
2013	10,000 AUD	-610,000 AUD	-10.52 M AUD
2014	0 AUD	0 AUD	0 AUD
2015	0 AUD	0 AUD	0 AUD
2016	0 AUD	-130,000 AUD	-2.84 M AUD
2017	4,200 AUD	-2.59 M AUD	-2.6 M AUD
2018	7,210 AUD	-1.92 M AUD	-1.82 M AUD
2019	8,730 AUD	-1.77 M AUD	-1.72 M AUD
2020	98,390 AUD	-2.33 M AUD	-3.25 M AUD
2021	510,980 AUD	-6.59 M AUD	-11.15 M AUD

2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
2	1	0	0	0	0	5	6	1	0	0	0	0	0	0	0	0	0	0	0
-	-50.00	-	-	-	-	-	20.00	-83.33	-	-	-	-	-	-	-	-	-	-	-
50.00	100.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
1,000	1,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	-2	-3	0	4	5	0	-1	0	0	0	0	0	-2	-1	-1	-2	-6
-	-	-	-	-	-	80.00	83.33	-	-	-	-	-	-	-	-	-	-	-	-
0	-1	-1	-3	-10	-11	3	3	-1	-1	-10	-10	0	0	-2	-2	-1	-1	-3	-11
-	-	-	200.00	233.33	10.00	-127.27	-	-133.33	-	900.00	-	-	-	-	-	-50.00	-	200.00	266.67
9.57	12.81	15.63	23.33	34.45	40.81	41.62	67.56	83.24	100.53	113.01	113.01	0	0	248.47	18.97	23.9	41.77	45.45	77.27
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021

1.3	1.16	0.37	2.86	0.13	0.51	2.36	15.76	1.96	1.77	0.74	0.21	0.03	1.73	3.12	0.67	1.45	7.56	7.33	5
0.03	0.02	0.05	0.24	0.06	0.01	0.1	0.01	5.37	0	0	0	0.02	0	0.08	0.03	0	0.06	0.02	0.22
100	60	220	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	47.5
0	0	0.23	0.13	0.17	2.26	0.03	0	0.01	0.02	0.23	0.03	0	0	0	0	0	0.01	0.03	0.38
1.43	1.24	0.87	3.23	0.36	2.78	2.49	15.77	7.34	1.79	0.97	0.24	0.05	1.74	3.2	0.7	1.45	7.63	7.37	5.65
0.14	0.2	0.14	0.5	0.32	0.01	0.01	0.01	0.01	0	0	0	0	0	0.01	0	0	0	0	1.73
0	0	0	0.35	0	0	3.63	4.18	12.25	25.05	15.3	3.97	2.76	0.11	0.08	0.03	0	0	0	0
0.01	0.01	0.01	4.26	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	15.12
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	11.03
1.3	1.22	2.5	9.11	11.91	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1.45	1.43	2.65	14.22	12.23	0.01	3.64	4.19	12.26	25.05	15.3	3.97	2.76	0.11	0.09	0.03	0	0	0	27.87
2.88	2.67	3.52	17.45	12.59	2.79	6.13	19.96	19.6	26.84	16.27	4.21	2.81	1.85	3.29	0.73	1.45	7.63	7.37	33.52

16.05	17.56	18.99	36.21	39.37	41.35	41.35	50.55	50.55	60.04	60.04	60.04	60.04	61.54	6.62	6.65	9.3	16.98	19.29	51.83
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
-13.74	-15.09	-16.22	-19.34	-28.32	-38.88	-35.68	-31.91	-33.52	-35.07	-45.52	-56.04	-59.15	-59.78	-3.75	-6.35	-8.13	-9.79	-12.75	-22.75
0	0	0	0	0	-420	0	0	0	0	550	-1,100	0	0	-41.27	-38.09	-42.72	-56.02	-62.91	-22.83
0	0	0	0	0	0	0	0.38	1.85	1.64	0.03	0.02	0	0	0	0	0	0	0	0
2.31	2.47	2.77	16.87	11.05	2.05	5.67	19.02	18.88	26.61	15.1	2.92	0.89	1.76	2.83	0.26	1.13	7.13	6.48	29.06
340	90	690	500	800	120	450	320	60	100	130	140	90	66.37	368.98	422.95	238.21	427.71	798.86	762.14
10	20	40	60	50	130	20	10	10	20	20	10	30	24.05	20.22	35.73	62.39	35.49	77.08	350.36
0	0	0	0	0	0	0	600	640	120	40	10	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	1	1.16	1.82	0	0.07	0	0	0	0	0
0	0	0	0	710	490	0	0	0	0	0	0	0	0	0	0	0	0	0	346.63
0.35	0.11	0.73	0.56	1.56	0.74	0.47	0.93	0.71	0.24	1.19	1.32	1.94	0.09	0.46	0.46	0.3	0.46	0.88	1.46
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	917.5
0.19	0.07	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2.06
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	10.28	22.04	28.66	23.19	29.82
0.19	0.07	0	0	0	0	0	0	0	0	0	0	0	0	0	0.01	0.02	0.03	0.02	3.01
0.54	0.18	0.73	0.56	1.56	0.74	0.47	0.93	0.71	0.24	1.19	1.32	1.94	0.09	0.46	0.47	0.32	0.49	0.9	4.46
2.85	2.65	3.5	17.43	12.61	2.79	6.14	19.95	19.59	26.85	16.29	4.24	2.83	1.85	3.29	0.73	1.45	7.63	7.37	33.52

2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2015	2016	2017	2018	2019	2020	2021
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	-1,000	-2,000	0	0	0	0	0	0	0	0	0	0	0	0	0	1,000
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	-1	0	-4	-5	-3	0	0	0	-1	0	0	0	0	-2	-1	-1	-2	-5
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
-1	0	-1	-5	-1	2	1	5	-12	0	0	0	2	0	0	0	0	0	2
0	0	-1	-4	-1	2	1	5	-12	0	0	0	2	0	0	0	0	0	3
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	1,000	0	-2,000	0	0	0	0	0	0
2	1	1	13	3	1	0	0	0	0	0	0	0	3	0	2	8	2	0
2	1	1	12	3	1	0	9	0	0	0	0	0	2	0	2	7	2	0
0	0	0	-1	0	0	0	9	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	-1	0	-5	-2	0	12	-14	-1	-1	-1	0	2	-4	-1	4	-3	-8
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

BARD1 Life Sciences Gross margin	BARD1 Life Sciences Profit margin	BARD1 Life Sciences EBIT margin	BARD1 Life Sciences Profit margin
2021	87.47 %	-1,290.51 %	-2,182.25 %
2020	87.47 %	-2,370.73 %	-3,306.79 %
2019	87.47 %	-20,305.96 %	-19,670.91 %
2018	87.47 %	-26,624.55 %	-25,205.27 %
2017	87.47 %	-61,721.43 %	-62,004.05 %
2016	87.47 %	0 %	0 %
2015	87.47 %	0 %	0 %
2014	87.47 %	0 %	0 %
2013	87.47 %	-6,100 %	-105,200.01 %
2012	87.47 %	-196.67 %	-3,483.33 %
2011	87.47 %	-515 %	-780 %
2010	87.47 %	32.88 %	-110.27 %
2009	87.47 %	83.41 %	54.26 %
2008	87.47 %	82.48 %	53.74 %
2007	87.47 %	2,333.33 %	-36,966.67 %
2006	47.37 %	-1,852.63 %	-5,378.95 %
2005	89.19 %	-613.51 %	-845.95 %
2004	84.13 %	-109.52 %	-179.37 %
2003	86.72 %	-45.31 %	-104.69 %
2002	84.89 %	-1.33 %	-8 %

	Gross margin	EBIT margin	Profit margin
2002	84.89 %	-1.33 %	-8 %
2003	86.72 %	-45.31 %	-104.69 %
2004	84.13 %	-109.52 %	-179.37 %
2005	89.19 %	-613.51 %	-845.95 %
2006	47.37 %	-1,852.63 %	-5,378.95 %
2007	87.47 %	2,333.33 %	-36,966.67 %
2008	87.47 %	82.48 %	53.74 %
2009	87.47 %	83.41 %	54.26 %
2010	87.47 %	32.88 %	-110.27 %
2011	87.47 %	-515 %	-780 %
2012	87.47 %	-196.67 %	-3,483.33 %
2013	87.47 %	-6,100 %	-105,200.01 %
2014	87.47 %	0 %	0 %
2015	87.47 %	0 %	0 %
2016	87.47 %	0 %	0 %
2017	87.47 %	-61,721.43 %	-62,004.05 %
2018	87.47 %	-26,624.55 %	-25,205.27 %
2019	87.47 %	-20,305.96 %	-19,670.91 %
2020	87.47 %	-2,370.73 %	-3,306.79 %
2021	87.47 %	-1,290.51 %	-2,182.25 %

Date	BARD1 Life Sciences Sales per Share	BARD1 Life Sciences EBIT per share	BARD1 Life Sciences Earnings per Share
2021	0.01 undefined	-0.09 undefined	-0.14 undefined
2020	0 undefined	-0.05 undefined	-0.07 undefined
2019	0 undefined	-0.04 undefined	-0.04 undefined
2018	0 undefined	-0.08 undefined	-0.08 undefined
2017	0 undefined	-0.14 undefined	-0.14 undefined
2016	0 undefined	-0 undefined	-0.01 undefined
2015	0 undefined	0 undefined	0 undefined
2014	0 undefined	0 undefined	0 undefined
2013	0 undefined	-0.01 undefined	-0.09 undefined
2012	0 undefined	-0.01 undefined	-0.09 undefined
2011	0 undefined	-0.01 undefined	-0.02 undefined
2010	0.02 undefined	0.01 undefined	-0.02 undefined
2009	0.1 undefined	0.09 undefined	0.06 undefined
2008	0.14 undefined	0.12 undefined	0.08 undefined
2007	0 undefined	0.02 undefined	-0.27 undefined
2006	0.01 undefined	-0.1 undefined	-0.3 undefined
2005	0.02 undefined	-0.1 undefined	-0.13 undefined
2004	0.04 undefined	-0.04 undefined	-0.07 undefined
2003	0.1 undefined	-0.05 undefined	-0.1 undefined
2002	0.24 undefined	-0 undefined	-0.02 undefined

	Sales per Share	EBIT per share	Earnings per Share
2002	0.24 AUD	-0 AUD	-0.02 AUD
2003	0.1 AUD	-0.05 AUD	-0.1 AUD
2004	0.04 AUD	-0.04 AUD	-0.07 AUD
2005	0.02 AUD	-0.1 AUD	-0.13 AUD
2006	0.01 AUD	-0.1 AUD	-0.3 AUD
2007	0 AUD	0.02 AUD	-0.27 AUD
2008	0.14 AUD	0.12 AUD	0.08 AUD
2009	0.1 AUD	0.09 AUD	0.06 AUD
2010	0.02 AUD	0.01 AUD	-0.02 AUD
2011	0 AUD	-0.01 AUD	-0.02 AUD
2012	0 AUD	-0.01 AUD	-0.09 AUD
2013	0 AUD	-0.01 AUD	-0.09 AUD
2014	0 AUD	0 AUD	0 AUD
2015	0 AUD	0 AUD	0 AUD
2016	0 AUD	-0 AUD	-0.01 AUD
2017	0 AUD	-0.14 AUD	-0.14 AUD
2018	0 AUD	-0.08 AUD	-0.08 AUD
2019	0 AUD	-0.04 AUD	-0.04 AUD
2020	0 AUD	-0.05 AUD	-0.07 AUD
2021	0.01 AUD	-0.09 AUD	-0.14 AUD

	Number of stocks
2002	9.57 M Aktien
2003	12.81 M Aktien
2004	15.63 M Aktien
2005	23.33 M Aktien
2006	34.45 M Aktien
2007	40.81 M Aktien
2008	41.62 M Aktien
2009	67.56 M Aktien
2010	83.24 M Aktien
2011	100.53 M Aktien
2012	113.01 M Aktien
2013	113.01 M Aktien
2014	113.01 M Aktien
2015	113.01 M Aktien
2016	248.47 M Aktien
2017	18.97 M Aktien
2018	23.9 M Aktien
2019	41.77 M Aktien
2020	45.45 M Aktien
2021	77.27 M Aktien

%	Name	Stocks	Change	Date
5.45 %	Moggs Creek Proprietary Ltd.	4,359,667	1,659,667	8/13/2020
5.10 %	Irminger-Finger (Irmgard)	4,080,000	-40,000	7/29/2021
14.50 %	Merchant Funds Management Pty Ltd	11,610,762	-25,596	8/24/2021
1.50 %	Traoj Pty. Ltd.	1,202,933	1,202,933	8/13/2020
1.38 %	Neate (David)	1,105,257	1,105,257	8/13/2020
1.29 %	Walker (Tony Michael)	1,028,918	0	8/13/2020
1.25 %	Rodgers (John Andrew)	997,474	619,048	8/13/2020
1.06 %	Emmanuel (Jeffrey Gerard)	845,294	-2,660,678	2/26/2021
0.97 %	Supergun Pty. Ltd.	776,468	0	8/13/2020
0.96 %	Ajava Holdings Pty. Ltd.	766,667	433,334	8/13/2020
0.70 %	Worldwise Enterprises Pty Ltd	556,865	20,593	8/13/2020
0.69 %	Wagner (Nathan Ryan)	551,937	551,937	8/13/2020
0.65 %	Laws (Barrie Ernest)	520,000	520,000	8/13/2020
0.65 %	Wilks (Lynne Maree)	516,667	129,334	8/13/2020
0.63 %	IFM Pty. Ltd.	505,556	505,556	8/13/2020
0.62 %	Hancock (Russell Kay)	500,000	500,000	8/13/2020
0.58 %	Pelagyia Pty. Ltd.	461,333	461,333	8/13/2020
0.51 %	Johnston (Max)	404,310	93,021	8/24/2021
0.41 %	Powell (Philip)	326,631	40,000	10/21/2021
0.18 %	Cumming (Geoffrey James Ph.D.)	144,447	19,354	8/24/2021
0 %	Gunzburg (Peter Lynton)	0	-1,312,740	7/28/2020

What values and corporate philosophy does BARD1 Life Sciences represent?

BARD1 Life Sciences Ltd represents values of innovation, excellence, and integrity. With a strong corporate philosophy focused on advancing the field of precision medicine, BARD1 Life Sciences Ltd seeks to improve patient outcomes through the development of diagnostic tests for early cancer detection. The company has a commitment to conducting research that contributes to the understanding of cancer biology and the identification of novel biomarkers. BARD1 Life Sciences Ltd places great importance on collaboration with leading institutions and industry partners to accelerate the translation of scientific discoveries into clinical practice. With a dedicated team, BARD1 Life Sciences Ltd strives to make a positive impact in the fight against cancer.

In which countries and regions is BARD1 Life Sciences primarily present?

BARD1 Life Sciences Ltd is primarily present in Australia.

What significant milestones has the company BARD1 Life Sciences achieved?

BARD1 Life Sciences Ltd has achieved several significant milestones. The company has successfully developed a novel and highly specific cancer diagnostic test, known as BARD1 Ovarian Cancer Test, which has shown promising results in early detection and monitoring of ovarian cancer. BARD1 has also established collaborations with renowned research institutions and pharmaceutical companies to further develop their portfolio of diagnostic and therapeutic products. The company has received recognition and grants for its innovative research and has secured partnerships to expand its global reach. BARD1 Life Sciences Ltd is committed to making impactful contributions to the field of cancer detection and treatment.

What is the history and background of the company BARD1 Life Sciences?

BARD1 Life Sciences Ltd is a biotechnology company based in Australia. Established in 2004, BARD1 focuses on developing and commercializing innovative diagnostics and therapeutics for cancer. The company is engaged in the research and development of novel diagnostic tests that detect specific cancer biomarkers. With a strong emphasis on early cancer detection and personalized medicine, BARD1 aims to improve patient outcomes through its cutting-edge technologies. The company has a dedicated team of scientists and researchers who work tirelessly to advance their product pipeline. BARD1 Life Sciences Ltd is committed to making a significant impact in the field of cancer diagnostics and improving the lives of patients worldwide.

Who are the main competitors of BARD1 Life Sciences in the market?

The main competitors of BARD1 Life Sciences Ltd in the market include other companies operating in the field of life sciences and diagnostics. Some notable competitors include companies like Illumina Inc., Thermo Fisher Scientific Inc., and QIAGEN N.V. These companies, like BARD1 Life Sciences Ltd, are engaged in the development and commercialization of innovative diagnostic tests and technologies. Their competition fosters continuous innovation and drives advancements in the life sciences industry.

In which industries is BARD1 Life Sciences primarily active?

BARD1 Life Sciences Ltd is primarily active in the biotechnology and life sciences industries.

What is the business model of BARD1 Life Sciences?

The business model of BARD1 Life Sciences Ltd is focused on the development and commercialization of cancer diagnostics and therapeutics. Specializing in precision oncology, BARD1 aims to identify and develop innovative biomarkers and companion diagnostics for early detection and personalized treatment of various cancers. By leveraging its proprietary technology and strategic collaborations, BARD1 Life Sciences is committed to improving patient outcomes and providing advancements in the field of cancer management.

What is the P/E ratio of BARD1 Life Sciences 2024?

The P/E ratio cannot be calculated for BARD1 Life Sciences at the moment.

What is the P/S ratio of BARD1 Life Sciences 2024?

The P/S cannot be calculated for BARD1 Life Sciences currently.

What is the AlleAktien quality score of BARD1 Life Sciences?

The AlleAktien quality score for BARD1 Life Sciences is 5/10.

What is the revenue of BARD1 Life Sciences 2024?

The revenue cannot currently be calculated for BARD1 Life Sciences.

How high is the profit of BARD1 Life Sciences 2024?

The profit cannot currently be calculated for BARD1 Life Sciences.

What is the business model of BARD1 Life Sciences

The BARD1 Life Sciences Ltd is an Australian biotechnology company specializing in the development of innovative cancer therapies. It focuses on the research and development of diagnostic and therapeutic products for various types of cancer. The company works closely with leading scientists and universities to develop and explore new products. One of the main divisions of BARD1 Life Sciences is the exploration of biomarker-based test procedures for early cancer detection. It develops innovative concepts to create fast, reliable, objective, and affordable diagnostic platforms. The products include tests for breast, cervical, prostate, and colon cancer. Another important area of BARD1 Life Sciences' business is the development of therapies for cancer patients. The company has developed a highly advanced drug discovery platform and collaborates closely with leading research institutions. The products range from immunotherapies to targeted therapies and chemotherapy. An important milestone in the history of BARD1 Life Sciences was the discovery of a new cancer gene called BARD1. The company found a new way to fight cancer through this discovery. The BARD1 gene is a tumor suppressor gene that malfunctions in many different types of cancer. The company has acquired exclusive rights to use this gene for diagnostic and therapeutic purposes. BARD1 Life Sciences has also formed partnerships with major pharmaceutical companies such as Bio-Rad Laboratories and Daiichi Sankyo to support product marketing and distribution. The company has also filed patents for several of its products to protect its innovations. The business model of BARD1 Life Sciences is based on the development of innovative products to improve cancer diagnosis and therapy. The different divisions include both diagnostics and therapeutics. The use of the BARD1 gene gives the company a unique competitive advantage and helps differentiate its products from those of competitors. Overall, BARD1 Life Sciences has established itself in the biotechnology industry and is working hard to develop new products that advance cancer research and improve patient care. With a strong pipeline of products and a growing number of partnerships, the company is well positioned to continue offering innovative solutions for cancer treatment.

What is the BARD1 Life Sciences dividend?

BARD1 Life Sciences pays a dividend of 0 AUD distributed over payouts per year.

How often does BARD1 Life Sciences pay dividends?

The dividend cannot currently be calculated for BARD1 Life Sciences or the company does not pay out a dividend.

What is the BARD1 Life Sciences ISIN?

The ISIN of BARD1 Life Sciences is AU000000BD12.

What is the BARD1 Life Sciences WKN?

The WKN of BARD1 Life Sciences is A2AL50.

What is the BARD1 Life Sciences ticker?

The ticker of BARD1 Life Sciences is BD1.AX.

How much dividend does BARD1 Life Sciences pay?

Over the past 12 months, BARD1 Life Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, BARD1 Life Sciences is expected to pay a dividend of 0 AUD.

What is the dividend yield of BARD1 Life Sciences?

The current dividend yield of BARD1 Life Sciences is .

When does BARD1 Life Sciences pay dividends?

BARD1 Life Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of BARD1 Life Sciences?

BARD1 Life Sciences paid dividends every year for the past 0 years.

What is the dividend of BARD1 Life Sciences?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is BARD1 Life Sciences located?

BARD1 Life Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von BARD1 Life Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of BARD1 Life Sciences from 9/7/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 9/7/2024.

When did BARD1 Life Sciences pay the last dividend?

The last dividend was paid out on 9/7/2024.

What was the dividend of BARD1 Life Sciences in the year 2023?

In the year 2023, BARD1 Life Sciences distributed 0 AUD as dividends.

In which currency does BARD1 Life Sciences pay out the dividend?

The dividends of BARD1 Life Sciences are distributed in AUD.

BARD1 Life Sciences Ticker	BARD1 Life Sciences FIGI
EUG:EO	BBG000QB5ZX7
EUG:E1	BBG000QB6535
EUGEUR:EO	BBG00D3DBFW8
EUGEUR:XJ	BBG00D3DBG47
EUGEUR:XS	BBG00D3DBGC8
EUGEUR:E1	BBG00D3DBGF5
EUG:XX	BBG00JN77BK3
EUGEUR:XX	BBG00JN8HXN9
EUG:EP	BBG00RCXXPQ4
EUG:EZ	BBG00RCXXPS2

Own the gold standard ✨ in financial data & analytics fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Price

Price

TickerBD1.AX

ISINAU000000BD12

WKNA2AL50

BARD1 Life Sciences stock price

Price

Overview

Intraday Feature

Total Return and Relative Price Change

Interpretation and Investment

BARD1 Life Sciences Stock Price History

BARD1 Life Sciences Revenue, EBIT, Net Income AU000000BD12 · A2AL50

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Yearly Analysis and Comparisons

Utilizing Expectations for Investment

Investment Insights

BARD1 Life Sciences Revenue, EBIT and net profit per share

BARD1 Life Sciences Income Statement, Balance Sheet, Cash Flow Statement

Keystats

Revenue and Growth

Gross Margin

EBIT and EBIT Margin

Income and Growth

Shares Outstanding

Interpreting Year to Year Comparison

Expectations and Predictions

Balance Sheet

Understanding the Balance Sheet

Assets

Liabilities

Equity

Year-to-Year Analysis

Interpreting the Data

BARD1 Life Sciences stock margins AU000000BD12 · A2AL50

Margin

Understanding Gross Margin

EBIT Margin Analysis

Revenue Margin Insights

Interpreting Expectations

Comparative Analysis

BARD1 Life Sciences Margin History

BARD1 Life Sciences Stock Sales Revenue, EBIT, Earnings per Share AU000000BD12 · A2AL50

Revenue, EBIT and Earnings per share

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

BARD1 Life Sciences Revenue, EBIT and net profit per share

BARD1 Life Sciences business model

BARD1 Life Sciences SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

BARD1 Life Sciences Eulerpool Fair Value

Fair Value

Understanding Fair Value

Income-Based Fair Value

Revenue-Based Fair Value

Dividend-Based Fair Value

Expectations and Forecasts

Comparative Analysis

BARD1 Life Sciences historical P/E ratio, EBIT, and P/S ratio.

BARD1 Life Sciences shares outstanding AU000000BD12 · A2AL50

Revenue, EBIT and Earnings per share

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

BARD1 Life Sciences Stock splits

BARD1 Life Sciences Earnings Estimates

BARD1 Life Sciences latest earnings and earnings surprises

BARD1 Life Sciences list of shareholders

Most common questions regarding BARD1 Life Sciences

What values and corporate philosophy does BARD1 Life Sciences represent?

In which countries and regions is BARD1 Life Sciences primarily present?

What significant milestones has the company BARD1 Life Sciences achieved?

Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Ticker
BD1.AX

ISIN
AU000000BD12

WKN
A2AL50